Ranolazine Dihydrochloride is an antianginal agent and partial fatty acid oxidation inhibitor primarily indicated for the treatment of chronic angina pectoris. By inhibiting the late sodium current in… Read more
Ranolazine Dihydrochloride is an antianginal agent and partial fatty acid oxidation inhibitor primarily indicated for the treatment of chronic angina pectoris. By inhibiting the late sodium current in cardiac cells, this medication optimizes myocardial energy metabolism to alleviate ischemic symptoms. Laboratories rely on high-quality reference standards of Ranolazine Dihydrochloride, along with its specific impurities, metabolites, and stable isotope-labeled compounds, to support rigorous analytical testing and quality control protocols. These materials are essential for accurate impurity profiling, method development, and the validation of analytical procedures throughout the pharmaceutical manufacturing lifecycle. Using these well-characterized standards ensures compliance with regulatory requirements and confirms the consistency and safety of drug products during stability studies and routine release testing.